United States Refractory Multiple Myeloma Market valuation $3.4 billion by 2030 - Exclusive Report by DatamIntelligence

"The Global Refractory Multiple Myeloma Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 3.4 billion by 2030 and CAGR of 4.7% during the forecast period 2024-2031." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/refractory-multiple-myeloma-market?sp

United States: Recent Industry Developments

✅ In September 2025, Bristol Myers Squibb launched a next-generation CAR-T therapy targeting BCMA for refractory multiple myeloma, demonstrating high response rates and durable remission in heavily pretreated patients. The therapy advances personalized oncology care.

✅ In August 2025, Janssen Pharmaceuticals expanded clinical trials for bispecific antibodies in refractory multiple myeloma, focusing on T-cell engagement and tumor eradication with improved safety profiles.

✅ In July 2025, Amgen introduced a novel BCMA-targeted antibody-drug conjugate (ADC) for refractory multiple myeloma, combining targeted cytotoxicity with reduced systemic toxicity to enhance patient outcomes.

✅ In June 2025, Gilead Sciences invested in R&D for next-generation cellular therapies and immunomodulatory treatments for refractory multiple myeloma, aiming to overcome resistance mechanisms and extend patient survival.

Japan: Recent Industry Developments

✅ In September 2025, Chugai Pharmaceutical launched innovative CAR-T therapies for refractory multiple myeloma with improved safety and efficacy profiles, targeting hard-to-treat patients in Japan.

✅ In August 2025, Takeda Pharmaceutical expanded clinical research for bispecific antibodies in multiple myeloma, focusing on T-cell redirection and sustained tumor response.

✅ In July 2025, Ono Pharmaceutical introduced BCMA-targeted ADCs for refractory multiple myeloma, designed to maximize cytotoxic effects while minimizing adverse events.

✅ In June 2025, Astellas Pharma invested in R&D for next-generation immunotherapies and combination regimens for refractory multiple myeloma, strengthening Japan's hematology treatment landscape.

Refractory Multiple Myeloma Market: Drivers

The refractory multiple myeloma (RMM) drugs market is experiencing strong growth, driven by the rising incidence of multiple myeloma, increasing number of patients unresponsive to standard therapies, and the need for novel treatment options. Refractory multiple myeloma occurs when patients do not respond or relapse after conventional treatments, creating demand for targeted therapies, immunotherapies, and combination regimens that improve survival and quality of life. Advances in monoclonal antibodies, CAR-T cell therapies, proteasome inhibitors, and immunomodulatory drugs are expanding treatment options and improving clinical outcomes. Increasing awareness among hematologists, patient advocacy programs, and early diagnosis initiatives are further supporting market adoption. Expansion of oncology care infrastructure, clinical trials, and supportive reimbursement policies is enhancing accessibility and treatment penetration.

Leading pharmaceutical companies such as Bristol Myers Squibb, Janssen Pharmaceuticals, Celgene, and Amgen are actively developing innovative therapies for RMM, focusing on efficacy, safety, and durable responses. Research into next-generation CAR-T therapies, bispecific antibodies, and combination treatments is broadening therapeutic possibilities. Strategic collaborations between biotech firms, hospitals, and research institutions are accelerating drug development and commercialization. Growing emphasis on personalized medicine, precision oncology, and patient-centric care is driving adoption of advanced therapies. With continuous innovation, rising multiple myeloma prevalence, and increasing demand for refractory disease management, the refractory multiple myeloma drugs market is poised for sustained global growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/refractory-multiple-myeloma-market?sp

Refractory Multiple Myeloma Market: Major Players

Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited and Genentech, Inc. among others.

Segment Covered in the Refractory Multiple Myeloma Market:

➥ By Drug Type: Proteasome Inhibitor, Immunomodulators, Anti-CD38 Monoclonal Antibody, Others

➥ By Route of Administration: Oral, Parenteral

➥ By Product Type: Tablet, Capsule, Solution, Suspension

➥ By End User: Hospitals, Surgical Centres/Clinics, Others

Research Process:

Both primary and secondary data sources have been used in the Refractory Multiple Myeloma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Refractory Multiple Myeloma Market Research Industry:

➠ Who leads the Refractory Multiple Myeloma industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Refractory Multiple Myeloma market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Refractory Multiple Myeloma market growth?
➠ What are the dominant sales and distribution strategies in the Refractory Multiple Myeloma industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=refractory-multiple-myeloma-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.